We further demonstrated that the second‐generation ALK‐TKI alectinib was much more effective than the first‐generation ALK‐TKI crizotinib in the in vivo imaging model, thus indicating the usefulness of alectinib against brain metastases induced by EML4‐ALK lung cancer 13. This evidence concerns the gene EML4 and lung cancer.